Beckman Coulter Life Sciences Acquires Blue Ocean Biomedical
By LabMedica International staff writers Posted on 18 Apr 2012 |
Beckman Coulter Life Sciences (Indianapolis, IN, USA) has acquired Blue Ocean Biomedical, LLC (Pembroke Pines, FL, USA), manufacturer of automated flow cytometry systems and reagents. The transaction provides Beckman Coulter Life Sciences with low complexity analyzers that integrate automated sample preparation and directly address emerging flow cytometry-market trends.
Driving growth through internal product development and through acquisition of differentiated businesses and technologies is a core strategy for Beckman Coulter Life Sciences. The transaction expands the company’s flow cytometry line and targets routine clinical analyses. Blue Ocean Biomedical products complement the company’s existing cytometry portfolio with instruments based on a “sample in, result out” (SIRO) approach that represents a fundamental change in the routine clinical analysis sector.
“This acquisition provides both immediate opportunity and long-term value,” said Scott Atkin, president, Beckman Coulter Life Sciences. “The simplification of customer workflows will be dramatic. We’ll be able to offer customers an extended line of market leading technology while expanding our reach within a key segment for flow cytometry.”
Blue Ocean Biomedical products provide the first true integration of sample preparation, handling, analysis and data management, and the only SIRO solution for clinical flow cytometry, and will enable Beckman Coulter Life Sciences to deliver an expanding portfolio of clinical testing to a broader global market.
“Our team has developed a line of truly unique instrument systems: essentially, the world’s first ‘load & go’ flow cytometers,” said Mike Brochu, CEO and cofounder of Blue Ocean Biomedical. “With its history of leadership and innovation in this field, Beckman Coulter has all the resources and technology needed to build on this platform and future systems for years to come.”
Related Links:
Beckman Coulter
Blue Ocean Biomedical
Driving growth through internal product development and through acquisition of differentiated businesses and technologies is a core strategy for Beckman Coulter Life Sciences. The transaction expands the company’s flow cytometry line and targets routine clinical analyses. Blue Ocean Biomedical products complement the company’s existing cytometry portfolio with instruments based on a “sample in, result out” (SIRO) approach that represents a fundamental change in the routine clinical analysis sector.
“This acquisition provides both immediate opportunity and long-term value,” said Scott Atkin, president, Beckman Coulter Life Sciences. “The simplification of customer workflows will be dramatic. We’ll be able to offer customers an extended line of market leading technology while expanding our reach within a key segment for flow cytometry.”
Blue Ocean Biomedical products provide the first true integration of sample preparation, handling, analysis and data management, and the only SIRO solution for clinical flow cytometry, and will enable Beckman Coulter Life Sciences to deliver an expanding portfolio of clinical testing to a broader global market.
“Our team has developed a line of truly unique instrument systems: essentially, the world’s first ‘load & go’ flow cytometers,” said Mike Brochu, CEO and cofounder of Blue Ocean Biomedical. “With its history of leadership and innovation in this field, Beckman Coulter has all the resources and technology needed to build on this platform and future systems for years to come.”
Related Links:
Beckman Coulter
Blue Ocean Biomedical
Latest Industry News
- Danaher and Johns Hopkins University Collaborate to Improve Neurological Diagnosis
- Beckman Coulter and MeMed Expand Host Immune Response Diagnostics Partnership
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance